News

Novasep builds €30m plant
Enlarge image

BusinessFranceGermanyEU

Novasep builds €30m plant

11.10.2012 - French chromatography specialist Novasep will create the world's largest chromatography plant for the pharmaceutical industry.

French bio-chromatography provider Novasep S.A. is set to build the world’s largest chromatography plant in Europe at its Mourenx site, for purification of pharmaceuticals. The company, which combined its technologies in large scale chromatography with German stationary phase provider instrAction two years ago, said the plant will be operational and validated within 18 months. Both the development of an advanced purification process and the plant expansion within the challenging timescale are results of the sharp increase in the projected demand for a large volume, highly purified API. New analyses from Frost & Sullivan predict the monoclonal antibody market in Europe to grow from US$19bn in 2011 to US$42.4bn in 2018 alone.

The €30m investment follows two other significant global investments in 2012: the opening of a new 2,000sqm facility in Shanghai and a €3m investment to expand the Highly Potent API (HPAPI) manufacturing capabilities in Le Mans. "Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, President and CEO of Novasep. The investment was supported by contributions of local authorities of Lacq, the General Council of Pyrénées Atlantiques, the Regional Council of Aquitaine, the Economic Development Bureau, DIRECCTE Aquitaine, the Prefecture of Pyrénées Atlantiques, the Total Group, and OSEO, France's innovation agency.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/novasep-builds-eur30m-plant.html

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

InnovationPolandEU

05.06.2015 Polish drug maker Polpharma has received a €45m loan from the European Investment Bank to further its biosimilar research. The operation is part of InnovFin, a new programme set up to support innovative research.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%

FLOP

  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%

TOP

  • PROTHENA PLC (IE)49.60 USD25.8%
  • DBV Technologies (F)52.00 EUR20.9%
  • BIOINVENT INTERNATIONAL AB (S)2.60 SEK16.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)20.50 SEK-57.1%
  • CELLECTIS (F)30.10 EUR-26.4%
  • NORDIC NANOVECTOR (N)27.00 NOK-22.9%

TOP

  • 4SC (D)4.52 EUR366.0%
  • ADOCIA (F)64.00 EUR352.3%
  • WILEX (D)3.69 EUR334.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-70.4%
  • NEOVACS (F)1.11 EUR-69.7%

No liability assumed, Date: 29.06.2015